09:15 AM EDT, 10/25/2024 (MT Newswires) -- Trinity Biotech ( TRIB ) said Friday it acquired EpiCapture, which is developing a test to monitor the risk of prostate cancer.

Trinity said it bought EpiCapture for an initial consideration of about $3 million, with an additional $0.5 million linked to the achievement of milestones.

The initial consideration was paid via the issuance of about 1.7 million American depository shares in Trinity, the company said.

Shares were 1% higher in recent premarket activity.

Price: 1.8500, Change: +0.02, Percent Change: +1.09